HIV 1 News and Research

RSS

Malaria, Africa's biggest killer

It's Africa's biggest killer, but it's not HIV. It causes economic losses of US$12 billion per year, but it's not a war. And it has slowed African economic growth by around 1.3 per cent per annum, but it’s not a famine.

2 Jun 2004

Chronic diseases are the largest cause of death in the world

The rising global burden of chronic diseases needs a coordinated effort from policy makers, advocates and health professionals, according to a special communication in the June 2 issue of the Journal of the American Medical Association (JAMA), a theme issue on Global Health.

1 Jun 2004

Thirty-five countries now face serious food shortages

Thirty-five countries now face serious food shortages, including two dozen in Africa, according to a report released by the United Nations Food and Agricultural Organization (FAO).

1 Jun 2004

Marijuana use does not appear to be associated with an increased risk of developing oral cancer

Contrary to previous research findings that have suggested a link, marijuana use does not appear to be associated with an increased risk of developing oral cancer, according to a large, population-based study led by researchers at Fred Hutchinson Cancer Research Center.

1 Jun 2004

Double-punch approach to vaccine design more effective

A study revealing new information about how viral proteins move between cells and alert the immune system suggests that a double-punch approach to vaccine design would make them more effective.

1 Jun 2004

Gay men casual about HIV

One in three HIV positive gay men don't know they are infected with the virus, suggests a large community study in Sexually Transmitted Infections.

1 Jun 2004

New UK HIV infection data

In the first three months of 2004, 1389 new diagnoses of HIV infection in the UK were reported. This brought the cumulative total to 62,709 since surveillance began in 1982.

1 Jun 2004

Fighting in the eastern Democratic Republic of Congo will affect HIV patients

Fighting in the eastern Democratic Republic of Congo (DRC) town of Bukavu - adjacent to the border with Rwanda - near the end of May has caused an MSF team there to seek refuge in the nearby UN compound.

1 Jun 2004

Blueprint for rational design of vaccines that induce desired T-cell responses

Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system’s “killer” T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.

27 May 2004

Human Genome Sciences has begun dosing patients with chronic hep C drug

Human Genome Sciences, Inc. announced today that it has begun dosing patients in a Phase 2 clinical trial of Albuferon™ (albumin-interferon alpha) in patients with chronic hepatitis C who are naïve to interferon-alpha treatments.

27 May 2004

Outlaw teen sexuality!

That’s right ban it, make it illegal, against the law, verboten. May is teen pregnancy prevention month. Let’s get real about the problem that is confronting us. The United States now has more teen pregnancies than any other country in the industrialized world. Over 1 million teenagers get pregnant every year and 78% of teen pregnancies are unintended.

26 May 2004

Australian HIV cases have increased 22 per cent over two years

New data released by Australia's NSW Health has revealed that HIV notifications increased by six per cent from 2002 to 2003. This follows a 15 per cent increase from 2001 to 2002, and represents a 22 per cent increase over two years.

26 May 2004

Zengen announces positive results of treatment for vaginal yeast infection

Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection.

25 May 2004

$3.5 million grant to develop AIDS vaccinations

Researchers at the Vaccine and Gene Therapy Institute (VGTI) and the Oregon National Primate Research Center at Oregon Health & Science University have received a $3.5 million grant from the National Institutes of Health to develop new methods for vaccinating humans against human immunodeficiency virus (HIV), the virus that causes AIDS.

25 May 2004

Bacteria found in the mouth can block the HIV virus

Certain strains of bacteria that occur naturally in the human mouth can snare the HIV virus and even cells it has infected, according to researchers at the University of Illinois at Chicago College of Dentistry. They report their findings today at the 104th General Meeting of the American Society for Microbiology.

25 May 2004

Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment

24 May 2004

Cystic Fibrosis Foundation Therapeutics awards $21 million to Vertex

Vertex Pharmaceuticals Incorporated has announced that it has expanded its drug discovery and development collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

24 May 2004

WHO to tackle heart disease, diabetes, cancers, road safety as well as diseases

The World Health Assembly, the supreme decision-making body of the World Health Organization, has raised global public health to a new level, by resolving to take more action to prevent death and illness resulting from heart disease, diabetes, cancers, road safety, and lack of access to health services as well as from diseases spread by viruses, bacteria and other dangerous microbes.

22 May 2004

Positive Chinese results for HIV test kit

Medical Services International Inc. has announced that it has received additional test results from the People's Republic of China related to its VScan HIV test kit. The results of an additional 1200 tests show that the test kit had a sensitivity of 99.4% and a specificity of 99.9%.

21 May 2004

Weekly cycles of once-daily anti-drugs could reduce cost of HIV treatment

In a small study conducted at the U.S. National Institutes of Health (NIH), researchers have shown that it may be feasible to treat HIV-infected patients with a simple, once-daily regimen of anti-HIV drugs given in pre-planned, 7-day-on, 7-day-off cycles. This approach is known formally as “short-cycle structured intermittent antiretroviral therapy” (SIT) or colloquially as the “7-7” approach.

20 May 2004